The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.
Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...
At Beth Israel Deaconess Medical Center, doctors say a once-fringe treatment for multiple myeloma is starting to look like a legitimate frontline weapon for some patients. CAR T cell therapy is ...
Zacks Investment Research on MSN
FDA accepts BMY's NDA for iberdomide combo in multiple myeloma
Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...
The FDA has accepted Bristol Myers Squibb (BMS)’s New Drug Application (NDA) for iberdomide for relapsed or refractory ...
Bristol-Myers Squibb Company hits a 52-week high as Breyanzi sales surge and AI imaging expands. Click for this updated look at BMY stock prospects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results